Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #1345

    Så er spørgsmålet om det vil give ekstra at tilføje dara http://onkologisktidsskrift.dk/behandlinger/lungekraeft/758-nsclc-patienter-overlever-med-lungekraeft-efter-tecentriq-behandling.html

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #1346

      Keytruda klarer sig også fint i nsclc. http://onkologisktidsskrift.dk/behandlinger/lungekraeft/763-peter-meldgaard-keytruda-kombination-oger-overlevelsen-markant-for-nsclc.html

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #1347

        Der kører ikke kombiforsøg med dara-pembro i nsclc. Kun i RRMM og et blandet i NHL.

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #1348

          Onclive article : Novel Approaches Emerge in AL Amyloidosis
          https://www.onclive.com/web-exclusives/novel-approaches-emerge-in-al-amyloidosis

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #1349

            Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - https://clinicaltrials.gov/ct2/show/study/NCT00574288?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=1&sect=X01256 - results posted

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #1350

              we have seen these before; it is GEN501

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #1351

                most of these hospitals finished
                recruiting now on this (D-RVd) trial, some even complete https://clinicaltrials.gov/ct2/show/study/NCT02874742?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=2&show_locs=Y#locn

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1352

                  Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP) was Terminated https://clinicaltrials.gov/ct2/show/NCT01612988?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=4
                  (which makes sense, it wasnt even a Novartis study)

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #1353

                    Onclive video : Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

                    • https://www.onclive.com/onclive-tv/dr-voorhees-on-treatments-for-patients-with-relapsed-multiple-myeloma
                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #1354

                      Very uplifting E L. They have also changed the primary completion date for the Griffin study from nov. 4. 2019 to dec. 31. 2018! A whole year. I wouldn't be surprised if they chose to file on that study. Even though it's only a phase 2. That would mean filing on the last frontline segment already next year.

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #1355

                        We already have Alcyone. Maia and Cassiopeia will com soon. The only left is Griffin. Then the whole fronline settting is covered.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #1356

                          Maybe it is a little early to expect a filing on the basis of Griffin. In November Winkel said: "Janssen is currently planning a Phase 3 study in D-RVd, and the Phase 2 data if
                          positive could be included in a compendium listing."

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            GeorgeBest
                            wrote on sidst redigeret af
                            #1357

                            E L & Bulder. So are so diligent, even in the weekends. Thanks a lot. We all profit from it.... 🙂

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              GeorgeBest
                              wrote on sidst redigeret af
                              #1358

                              You are so diligent,..

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bikube
                                wrote on sidst redigeret af
                                #1359

                                Seeking Alfa - Under Stocks To Watch - Upcoming stoch splits: Genmab (OTCPK:GMXAY) 5-for-1.

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  peter12
                                  wrote on sidst redigeret af
                                  #1360

                                  Det lyder mærkeligt ? https://seekingalpha.com/article/4167213-stocks-watch-apple-fomc-china-tap?page=2

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    pauly
                                    wrote on sidst redigeret af
                                    #1361

                                    Mange har jo ønsket et split, men det er da nyt. Gu´ved om det også kommer til den danske notering hvis det altså passer

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      peter12
                                      wrote on sidst redigeret af
                                      #1362

                                      Mon ikke det er en and ? Så skal JDW da have skiftet mening. Måske nogle store investorer kan presse dem.

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bikube
                                        wrote on sidst redigeret af
                                        #1363

                                        Jeg kan ikke få øje på, hvorfor man skulle lave split i U S. Kursen derovre er $103. Der har jo længe været nogle, der har ønsket et split, men JvDW har jo hidtil afvist, at der skulle være planer derom. Det kan da være, at han læser med, og dementerer eller bekræfter rygtet.

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          pauly
                                          wrote on sidst redigeret af
                                          #1364

                                          Næh det
                                          er nok en and.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger